Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663383 | 0.90 | TRPA1 (0.35) | CCR3OPRM1OPRD1OPRK1 | |
| SCHEMBL4664186 | 0.88 | CCR3 (0.43) | CCR3OPRM1OPRD1OPRK1CCR5 | |
| SCHEMBL4663731 | 0.85 | OPRM1 (0.36) | OPRM1OPRD1OPRK1CCR5SMN1; SMN2 | |
| SCHEMBL4663413 | 0.85 | CXCR4 (0.39) | OPRM1OPRD1OPRK1CCR5SMN1; SMN2 | |
| SCHEMBL4663652 | 0.85 | SLC6A2 (0.34) | OPRM1OPRD1OPRK1CYP3A4CYP2D6 | |
| SCHEMBL4665352 | 0.83 | OPRM1 (0.35) | CCR3OPRM1OPRD1OPRK1CCR5 | |
| SCHEMBL4665361 | 0.82 | SLC6A4 (0.43) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6943211 | 0.82 | OPRK1 (0.42) | CCR3OPRM1OPRD1OPRK1 | |
| SCHEMBL4663381 | 0.81 | SMN1; SMN2 (0.41) | OPRM1OPRD1OPRK1SMN1; SMN2TDP1 | |
| SCHEMBL4665434 | 0.81 | GMNN (0.39) | OPRM1OPRD1OPRK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | claimed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | claimed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | claimed |
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| EP-1368299-B1 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1571140-A1 | C-substituted cyclohexylmethylamine derivatives | Grünenthal GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-1368299-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002030870-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | CNR2, CNR1, HNMT | CCR3 144/4885OPRM1 5/4885OPRD1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.